
Feature|Videos|July 23, 2025
Rethinking Market Strategy within a Patient-Centric Era
A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.
Advertisement
Episodes in this series

As the series closes, the panel reflects on an often underrepresented but crucial stakeholder: the patient. The discussion underscores the need for a more patient-centered market access strategy—one that incorporates health equity, diagnostic and treatment journey support, and clearer communication around cost and adherence.
Key discussion topics include:
- How social determinants of health (SDOH) shape real-world treatment access.
- The growing need for payer transparency and patient trust in the marketplace.
- Strategies to engage patients early in development to ensure success.
Advertisement
Related to this article

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Innogen grants Arcera exclusive rights to its long-acting GLP-1 receptor agonist across Africa, Eastern Europe, Latin America and the Middle East.

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
5


